Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity

Leukemia

Volumn 28, Issue 9, 2014, Pages 1915-1918

  Pippa, R ^a   Dominguez, A ^a   Christensen, D J ^b   Moreno Miralles, I ^a   Blanco Prieto, M J ^c   Vitek, M P ^b   Odero, M D ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Oncotide Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; FINGOLIMOD; INHIBITOR PROTEIN; OP 449; PEPTIDE DERIVATIVE; PHOSPHOPROTEIN PHOSPHATASE 2A; SET PROTEIN; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; HL 60 CELL LINE; HUMAN; HUMAN CELL; LETTER; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

CELL LINE, TUMOR; HISTONE CHAPERONES; HUMANS; LEUKEMIA, MYELOID, ACUTE; PEPTIDES; PROPYLENE GLYCOLS; PROTEIN PHOSPHATASE 2; SPHINGOSINE; TRANSCRIPTION FACTORS;

EID: 84908300167     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.141     Document Type: Letter

References (15)

1. Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013; 14: e229-e238
2. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia. 2011; 25: 606-614
3. Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez MA, Calasanz MJ., et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 2012; 97: 543-550
4. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ., et al. PP2A-Activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013; 123: 4144-4157
5. Estella Hermoso-de Mendoza A, Castello-Cros R, Imbuluzqueta E, Cirauqui C, Pippa R, Odero MD., et al. Lipid nanosystems enhance the bioavailability and the therapeutic efficacy of FTY720 in acute myeloid leukemia. J Biomed Nanotechnol. 2014 (in press
6. Agarwal A, Mackenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW., et al. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res. 2014; 20: 2092-2103
7. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011; 30: 2504-2513
8. Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G., et al. Antagonistic activities of the immunomodulator and PP2A-Activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013; 122: 1923-1934
9. Saito S, Miyaji-Yamaguchi M, Shimoyama T, Nagata K. Functional domains of template-Activating factor-I as a protein phosphatase 2A inhibitor. Biochem Biophys Res Commun. 1999; 259: 471-475
10. Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I., et al. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Lett. 2011; 585: 2653-2659
11. Yu G, Yan T, Feng Y, Liu X, Xia Y, Luo H., et al. Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease. Neurobiol Aging. 2013; 34: 1748-1758
12. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J., et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013; 5: 105-121
13. Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, Li F., et al. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol. 2011; 186: 2535-2542
14. Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G., et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013; 122: 3034-3044
15. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW., et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007; 117: 2408-2421. 1918-1922